PMC3191146_01
PMC3191146_02
Annually reported cases of flupirtine induced liver injury.. Annually spontaneously hepatobiliary adverse events reported for flupirtine (black) and proportion of cases rated to be 'highly probable' or 'probable' according to the CIOMS score (grey).
pone.0025221.g001.jpg
PMC3191146_02_pone.0025221.g001.jpg
pone-0025221-g001
Furthermore, as shown in Figures S1 and S2 of the supplementary data, the number of drugs given and the severity of liver damage appeared to be linked in patients suffering from a variety of pain conditions to either the use NSAIDs or other drugs known or suspected to be hepatotoxic.
Results of liver function tests of spontaneously reported ADRs.. Scatter plots of maximum AST (A), ALT (B), and bilirubin (C) levels (given inxULN) in relation to the daily dose (left panel), cumulative doses (daily dose (mg)xduration of drug exposure (days), middle panel), and in relation to the time to onset (right panel) of the ADRs in cases of suspected hepatobiliary adverse events associated with flupirtine exposure.
pone.0025221.g002.jpg
PMC3191146_02_pone.0025221.g002.jpg
pone-0025221-g002
Furthermore, as shown in Figures S1 and S2 of the supplementary data, the number of drugs given and the severity of liver damage appeared to be linked in patients suffering from a variety of pain conditions to either the use NSAIDs or other drugs known or suspected to be hepatotoxic.
Flupirtine hyper-sensitivity of a 53-year-old female patient.. Laboratory results of a 53-year-old female patient after exposure and re-exposure to flupirtine. She experienced icterus with markedly increased serum transaminase levels. Upon discontinuation transaminase levels decreased. On day 6 of hospital admission re-exposure to an unknown dose of flupirtine resulted in a recurrent increase of laboratory values.
pone.0025221.g003.jpg
PMC3191146_02_pone.0025221.g003.jpg
pone-0025221-g003
Re-exposure (dose unknown) on day 5 of admission resulted in a recurrent increase of laboratory parameters (see Figure 3 below).